6 New Data Sets Available for Public Access Use!

In the last month, we at CDD have released six new Data Sets on our Public Access Page!

Three of these Data Sets are from TimTec, a chemical vendor we have collaborated with before.  The first new TimTec library is their Diversity Set, a screening library of about 10,000 diverse compounds.  Second is a set of OGlcNAc Transferase Inhibitor Analogs.  Finally, TimTec’s ActiTarg-K Kinase modulators finish out the trio.  For a more detailed description of these three sets, click here.

We have also added a set of nearly 2,000 compounds screened for anti-Malaria activity (3D7 and Dd2), provided by the Johns Hopkins Clinical Compound Library.

On the Tuberculosis front, CDD’s own Sean Ekins, PhD has released a set of thirty-two 1,3 benzothiazin-4-one compounds published by Markov et. al at the NM4TB consortia.

Finally, Robert Goldman of the Southern Research Institute has made available a set of compounds screened against Mtb H37Rv.  This set of more than 200,000 compounds was collected by the Molecular Small Molecule Repository (MLSMR) in the spring of last year.

If you want to gain access to these new Data Sets, please register on our Public Access page.

Here at CDD, we’ve acknowledged the importance of collaboration in advancing drug discovery research. While our software can function as a stand-alone database for archiving and mining public data, researchers have the ability to take their work to the next level and selectively collaborate with their peers.

Around the globe, the idea of collaboration in the field of drug discovery research is gathering momentum.  In the last year, an organization called the Pistoia Alliance (named for the city in Tuscany where the group held its first meeting) has put forth the bold notion of collaboration between large pharmaceutical companies.  Currently, members of the discovery informatics teams of GSK, AstraZeneca, Pfizer, and Novartis are on board.  They have established a non-profit organization and a wiki group on SourceForge.net. 

It will be clear at some point that the alliance will open up to new members who believe in the ideology of sharing elements of the drug discovery research pipeline.  As a truly collaborative operation, projects undertaken by Pistoia will be determined based on the collective input of all of its members.  It will be exciting to witness the results of this alliance!

For more information, visit the Pistoia Alliance at their SourceForge.net site.

CDD has joined the fray of Web 2.0 on-the-go!

Last week, Barry Bunin, PhD (our CDD CEO) gave a presentation at the Bio-IT conference in Boston. Les Jordan of the Microsoft Life Sciences division, while sitting in the audience, posted a tweet about Barry’s talk, even providing a link to our website.

With the Twitter craze in full force, it’s great to see CDD getting exposure.  Hopefully we continue to inspire more tweets!